Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OMERBullishAnalyst Ratingnews

High materiality7/10

Cantor Upgrades OMER on Yartemlea Strength, Sets $22 Target

Sep 22, 2026, 2:43 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The upgrade to Overweight with a $22 target, plus visibility on NTAP and J-code reimbursement, can lead to multiple expansion and upside potential beyond the $20 area, as investors price in stronger adoption and revenue potential.

AI summary

What happened, with direct paths to the underlying reporting

Cantor Fitzgerald upgrades OMER to Overweight with a $22 target after Yartemlea's stronger-than-expected launch. Payer support via NTAP and a J-code, plus Q2 revenue of $28.5M (up 11% sequentially), bolster long-term adoption and peak sales potential. The stock rose about 12%, signaling potential further upside.

Cantor upgrades OMER to Overweight after strong Yartemlea launch.
Target lifted to $22; Cantor sees larger-than-expected potential.
NTAP status and J-code improve payer access for Yartemlea.
Q2 Yartemlea revenue $28.5M, up 11% sequentially; stock hits 52-week high.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.